Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks

Alternative splicing is regulated by multiple RNA-binding proteins and influences the expression of most eukaryotic genes. However, the role of this process in human disease, and particularly in cancer, is only starting to be unveiled. We systematically analyzed mutation, copy number and gene expression patterns of 1348 RNA-binding protein (RBP) genes in 11 solid tumor types, together with alternative splicing changes in these tumors and the enrichment of binding motifs in the alternatively spliced sequences. Our comprehensive study reveals widespread alterations in the expression of RBP genes, as well as novel mutations and copy number variations in association with multiple alternative splicing changes in cancer drivers and oncogenic pathways. Remarkably, the altered splicing patterns in several tumor types recapitulate those of undifferentiated cells. These patterns are predicted to be mainly controlled by MBNL1 and involve multiple cancer drivers, including the mitotic gene NUMA1. We show that NUMA1 alternative splicing induces enhanced cell proliferation and centrosome amplification in non-tumorigenic mammary epithelial cells. Our study uncovers novel splicing networks that potentially contribute to cancer development and progression.

[1]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[2]  Gael P. Alamancos,et al.  Leveraging transcript quantification for fast computation of alternative splicing profiles , 2014, bioRxiv.

[3]  H. Deeg,et al.  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. , 2015, Cancer cell.

[4]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[5]  Eduardo Eyras,et al.  Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer , 2015, Nucleic acids research.

[6]  Caterina Marchiò,et al.  SF3B1 mutations constitute a novel therapeutic target in breast cancer , 2014, The Journal of pathology.

[7]  P. Rogan,et al.  Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer , 2014, Scientific Reports.

[8]  D. Bates,et al.  Hallmarks of alternative splicing in cancer , 2014, Oncogene.

[9]  Michael R. Green,et al.  SRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene. , 2014, Biochimica et biophysica acta.

[10]  P. Sharp,et al.  Building Robust Transcriptomes with Master Splicing Factors , 2014, Cell.

[11]  Anil Wipat,et al.  Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons , 2014, Nature Communications.

[12]  Dan Chen,et al.  The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. , 2014, Cancer cell.

[13]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[14]  A. Mele,et al.  Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer , 2014, eLife.

[15]  Monika Heiner,et al.  The RNA-Binding Protein QKI Suppresses Cancer-Associated Aberrant Splicing , 2014, PLoS genetics.

[16]  Chandra Sekhar Pedamallu,et al.  A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events , 2014, PloS one.

[17]  A. Krainer,et al.  Splicing factor SRSF6 promotes hyperplasia of sensitized skin , 2014, Nature Structural &Molecular Biology.

[18]  M. Carmo-Fonseca,et al.  The Potential of Targeting Splicing for Cancer Therapy , 2014 .

[19]  Rakesh Kumar,et al.  Nuclear Signaling Pathways and Targeting Transcription in Cancer , 2014, Cancer Drug Discovery and Development.

[20]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[21]  J. Valcárcel,et al.  RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. , 2013, Molecular cell.

[22]  J. Tazi,et al.  MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation , 2013, Nature Communications.

[23]  P. Gönczy,et al.  NuMA phosphorylation by CDK1 couples mitotic progression with cortical dynein function , 2013, The EMBO journal.

[24]  Jeroen Krijgsveld,et al.  The RNA-binding protein repertoire of embryonic stem cells , 2013, Nature Structural &Molecular Biology.

[25]  Brendan J. Frey,et al.  A compendium of RNA-binding motifs for decoding gene regulation , 2013, Nature.

[26]  Eric T. Wang,et al.  MBNL proteins repress ES-cell-specific alternative splicing and reprogramming , 2013, Nature.

[27]  Kami Kim,et al.  Discovery of a Splicing Regulator Required for Cell Cycle Progression , 2013, PLoS genetics.

[28]  M. Bordonaro.  Crosstalk between Wnt Signaling and RNA Processing in Colorectal Cancer , 2013, Journal of Cancer.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[30]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[31]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[33]  Norman E. Davey,et al.  Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins , 2012, Cell.

[34]  Richard Bonneau,et al.  The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. , 2012, Molecular cell.

[35]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[36]  Luigi Coppola,et al.  Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. , 2011, Cancer research.

[37]  R. Klemke,et al.  Abstract 4464: Ciclopirox Olamine alters PEAK-1-mediated cytoskeleton organization and invasion of metastatic cancer cells , 2011 .

[38]  Yu Xue,et al.  GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. , 2011, Protein engineering, design & selection : PEDS.

[39]  C. Deng,et al.  SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance , 2010, International journal of biological sciences.

[40]  B. Blencowe,et al.  Global Profiling and Molecular Characterization of Alternative Splicing Events Misregulated in Lung Cancer , 2010, Molecular and Cellular Biology.

[41]  J. Minna,et al.  hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. , 2010, The Journal of clinical investigation.

[42]  Jing Liu,et al.  LGN regulates mitotic spindle orientation during epithelial morphogenesis , 2010, The Journal of cell biology.

[43]  K. Suzuki,et al.  The multi‐functional serpin, protein C inhibitor: beyond thrombosis and hemostasis , 2008, Journal of thrombosis and haemostasis : JTH.

[44]  R. Tibshirani,et al.  Sparse inverse covariance estimation with the graphical lasso. , 2008, Biostatistics.

[45]  W. Tan,et al.  Functional Variants in Cell Death Pathway Genes and Risk of Pancreatic Cancer , 2008, Clinical Cancer Research.

[46]  P. Jeanteur.  [RNA and cancer]. , 2008, Bulletin du cancer.

[47]  Chen-Yang Shen,et al.  Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[48]  Xiang-Dong Fu,et al.  Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis , 2007, Molecular and Cellular Biology.

[49]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[50]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[51]  S. Stamm,et al.  Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. , 2006, Cancer research.

[52]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[53]  Zsuzsanna Dosztányi,et al.  IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..

[54]  Stefan Kammerer,et al.  Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[56]  M. Newman,et al.  Finding community structure in very large networks. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[57]  Charles Elkan,et al.  Fitting a Mixture Model By Expectation Maximization To Discover Motifs In Biopolymer , 1994, ISMB.